Loading
Addus HomeCare Corp Stock: price and insider trades · United States
Addus HomeCare Corp: what insiders have been doing
Addus HomeCare Corp belongs to the Healthcare & Pharma sector. Filings by its managers are published through SEC (Form 4). From 18 October 2025 to 18 October 2026, the disclosure feed for Addus HomeCare Corp logged 44 filings by 17 insiders.
The flow runs one way only: 26 sales worth €2.1M, from 11 insiders, and no purchase. The totals exclude 1 filing filed without an amount. One trade stands out by size: a sale of €452k from Allison R Dirk, disclosed on 26 February 2026.
Filings reach the SEC (Form 4) feed a median of 1 day after the trade. The legal deadline for a Form 4 is two business days after the transaction. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning.
Compared with its exchange (5,812 companies, median 19 filings), a count of 44 filings is above the norm. Looking back to 2016, when coverage begins, insiders filed no purchases and 156 sales. The 10-K for the year ended 31 December 2025 shows 1.42 bn USD of revenue and 95.9 m USD of net income.
In the same sector, recent insider purchases at Cooper Companies, Inc. and Cytosorbents Corp also feature in our signals. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
285
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
€20M
156 ops. · all time
Who traded when
BuySaleR. Dirk Allison8 sales
Brian Poff6 sales
Cliff Donald Blessing6 sales
Esteban Lopez6 sales
Monica Raines6 sales
Roberton James Stevenson6 sales
+7 other insiders
Analyst consensus: bullish or bearish?
Analysts rate Addus HomeCare Corp Buy (bullish), based on 13 analysts. Average price target: US$134.08.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 9,920 of 24,148 companies
56.1
score / 100
Value54
Quality59
FCF yld4.8%
Earn yld4.4%
EV/EBITDA14.9x
ROE9.7%
Gross mgn32%
Net mgn6.7%
Debt/EBITDA1.1x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$116.62
Analyst consensus
13 analystsBuy
US$96.00Target US$134.08(+15%)US$155.00
Income statement
RevenueUS$1.4B
Gross profitUS$461.9M32% margin
EBITDAUS$157.5M11% margin
Net incomeUS$95.9M7.1% margin
Valuation
PER (trailing)20.0x
PER (forward)15.5x
P/Book1.9x
Beta0.83
Balance sheet & cash
Market capUS$2.2B
Total debtUS$171.4M
Free Cash FlowUS$103.8M
Debt / Equity9%
Profitability & ownership
ROE9.7%
ROA6.3%
% insiders2.8%
% institutions107.8%
Last declaration on 23 June 2026
Declarations285 total
288 sharesCommon StockSEC:0001437749-26-021450:0
1,449 sharesCommon StockSEC:0001437749-26-020317:0
1,449 sharesCommon StockSEC:0001437749-26-020318:0
1,449 sharesCommon StockSEC:0001437749-26-020321:0
1,449 sharesCommon StockSEC:0001437749-26-020315:0
1,449 sharesCommon StockSEC:0001437749-26-020319:0
1,449 sharesCommon StockSEC:0001437749-26-020322:0
250 shares@ US$93.000.0012% mcap5.9% of flowCommon StockSEC:0001437749-26-018260:0
250 shares@ US$93.000.0012% mcap5.9% of flowCommon StockSEC:0001437749-26-018105:0
178 shares@ US$93.610.0008% mcap4.8% of flowCommon StockSEC:0001437749-26-013038:0
224 shares@ US$102.155.9% of flowCommon StockSEC:0001437749-26-006622:0
437 shares@ US$106.9912.0% of flowCommon StockSEC:0001437749-26-005888:0
567 shares@ US$107.355.9% of flowCommon StockSEC:0001437749-26-005887:0
350 shares@ US$107.1410.7% of flowCommon StockSEC:0001437749-26-005886:0
592 shares@ US$107.352.2% of flowCommon StockSEC:0001437749-26-005885:0
704 shares@ US$107.354.8% of flowCommon StockSEC:0001437749-26-005883:0
733 shares@ US$106.984.7% of flowCommon StockSEC:0001437749-26-005882:0
817 shares@ US$106.983.2% of flowCommon StockSEC:0001437749-26-005881:0
2,041 shares@ US$106.984.8% of flowCommon StockSEC:0001437749-26-005880:0
4,988 shares@ US$106.984.1% of flowCommon StockSEC:0001437749-26-005879:0
4,535 shares@ US$114.914.0% of flowCommon StockSEC:0001437749-26-005315:1
1,858 shares@ US$114.914.7% of flowCommon StockSEC:0001437749-26-005321:1
737 shares@ US$114.913.1% of flowCommon StockSEC:0001437749-26-005322:1
666 shares@ US$114.914.5% of flowCommon StockSEC:0001437749-26-005323:1
25 of 285 declarations
About Addus HomeCare Corp
Addus HomeCare Corp. (ticker: ADUS) is a U.S.-based home care services company listed on the NASDAQ in the United States. For French-speaking investors, it is best viewed as a specialized healthcare-services provider operating in a segment supported by long-term demographic and policy trends: an aging population, patient preference for care delivered at home, and the ongoing pressure on public and private payers to reduce the cost of post-acute and chronic care. Addus operates three core business lines: personal care, hospice, and home health. Its services are delivered primarily in patients’ homes under arrangements with federal, state and local government agencies, managed care organizations, commercial insurers, and private individuals. A meaningful share of its consumer base is “dual eligible,” meaning beneficiaries qualify for both Medicare and Medicaid.
The company traces its origins to 1979, when it began providing home care services. Addus was incorporated in Delaware in July 2006 and completed its initial public offering in October 2009. Over time, the company has broadened its footprint through a mix of organic growth and acquisitions. Its corporate office is in Frisco, Texas, and it also maintains a support center in Downers Grove, Illinois. As of year-end 2024, Addus was serving customers across 23 states through approximately 258 offices, giving it a diversified but still regionally focused operating base.
Read moreShow less
From a competitive standpoint, Addus differentiates itself through local density, payer relationships, and the gradual expansion of clinical capabilities. Management’s strategy has been to deepen presence in existing states while adding clinical care services to complement personal care. In selected markets, the company now offers all three levels of care, which can improve patient retention, referral relationships, and cross-selling opportunities. This model is particularly relevant in home-based care, where scale, reimbursement management, and local execution matter materially. In 2024, Addus reported net service revenue of $1.15 billion, with personal care representing the largest share of revenue, followed by hospice and home health. The company served approximately 105,000 discrete consumers during the year.
Recent developments underscore the company’s acquisition-led growth strategy. On December 2, 2024, Addus completed the acquisition of Gentiva’s personal care business, a transaction that strengthened its market density, especially in Texas. In 2025, it continued to expand through the acquisition of Helping Hands Home Care Service. More recently, in early 2026, Addus reported strong full-year 2025 results and highlighted supportive state funding trends, including a significant rate increase in Texas effective September 1, 2025. Overall, ADUS stands out as a NASDAQ-listed U.S. home care platform with exposure to durable structural demand, recurring reimbursement relationships, and a proven acquisition strategy.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
